Boston Trust Walden Corp Has $102.73 Million Stock Holdings in Waters Corporation $WAT

Key Points

• Boston Trust Walden Corp increased its holdings in Waters Corporation by 2.3%, owning 294,325 shares valued at approximately $102.73 million as of the end of the last quarter.
• Waters Corporation's stock performance shows a market capitalization of $20.05 billion, with a P/E ratio of 30.37 and a 1-year high of $423.56.
• Analysts have provided a consensus rating of "Moderate Buy" for Waters, with a price target average of $377.56.

Boston Trust Walden Corp increased its position in shares of Waters Corporation (NYSE:WAT - Free Report) by 2.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 294,325 shares of the medical instruments supplier's stock after buying an additional 6,525 shares during the quarter. Boston Trust Walden Corp owned 0.49% of Waters worth $102,731,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in WAT. Brighton Jones LLC grew its position in Waters by 112.9% during the fourth quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier's stock worth $471,000 after buying an additional 673 shares in the last quarter. GAMMA Investing LLC lifted its stake in Waters by 36.6% during the first quarter. GAMMA Investing LLC now owns 1,797 shares of the medical instruments supplier's stock worth $662,000 after purchasing an additional 481 shares during the period. CX Institutional bought a new position in Waters during the first quarter worth about $75,000. Fifth Third Bancorp lifted its stake in Waters by 2.3% during the first quarter. Fifth Third Bancorp now owns 2,273 shares of the medical instruments supplier's stock worth $838,000 after purchasing an additional 52 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Waters by 169.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 11,619 shares of the medical instruments supplier's stock worth $4,283,000 after purchasing an additional 7,301 shares during the period. 94.01% of the stock is owned by institutional investors and hedge funds.

Waters Stock Performance

NYSE:WAT opened at $336.83 on Tuesday. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $423.56. The firm has a 50 day moving average of $300.98 and a 200-day moving average of $323.39. The company has a current ratio of 1.75, a quick ratio of 1.22 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $20.05 billion, a P/E ratio of 30.37, a price-to-earnings-growth ratio of 3.09 and a beta of 1.04.

Waters (NYSE:WAT - Get Free Report) last posted its earnings results on Thursday, May 19th. The medical instruments supplier reported $2.29 earnings per share (EPS) for the quarter. Waters had a net margin of 21.71% and a return on equity of 38.60%. The company had revenue of $608.55 million during the quarter. As a group, sell-side analysts anticipate that Waters Corporation will post 12.86 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Robert W. Baird cut their price target on shares of Waters from $374.00 to $352.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. Bank of America raised their price target on shares of Waters from $370.00 to $375.00 and gave the stock a "neutral" rating in a research note on Thursday, June 26th. Rothschild & Co Redburn assumed coverage on shares of Waters in a research note on Wednesday, October 8th. They set a "buy" rating and a $390.00 price target for the company. Jefferies Financial Group set a $385.00 price target on shares of Waters and gave the stock a "buy" rating in a research note on Monday, August 4th. Finally, Scotiabank restated a "sector outperform" rating and set a $465.00 price target on shares of Waters in a research note on Friday, July 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, Waters presently has a consensus rating of "Moderate Buy" and a consensus price target of $377.56.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.